Literature DB >> 7241161

The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration.

W J Meyler, H Bakker, J J Kok, S Agoston, H Wesseling.   

Abstract

In 25 patients with spasticity, pharmacokinetics and effects of dantrolene sodium were investigated after prolonged administration. A beneficial effect occurred in seven patients. The results were better on 100 mg daily than on a higher daily dose. An increase of the daily dose from 200 to 400 mg was not associated with higher blood levels. Many side effects were noted such as: anorexia, nausea, drowsiness, depression and muscle weakness. From this study we conclude that dantrolene sodium is a muscle relaxant with a weak to moderate effect in patients with spasticity; the effect at doses higher than 200 mg daily is probably poor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7241161      PMCID: PMC490957          DOI: 10.1136/jnnp.44.4.334

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  The effect of dantrium on spasticity of hemiplegic patients.

Authors:  B Jonsson; H Ladd; I Afzelius-Frisk; A M Lindberg-Broman
Journal:  Acta Neurol Scand       Date:  1975-05       Impact factor: 3.209

3.  Effect of radical neck dissection on total rehabilitation of the laryngectomee.

Authors:  P S King; F R Lewis; J L Weddle; E W Fowlks
Journal:  Am J Phys Med       Date:  1973-02

4.  Determination of dantrolene in biological specimens containing drug-related metabolites.

Authors:  R D Hollifield; J D Conklin
Journal:  J Pharm Sci       Date:  1973-02       Impact factor: 3.534

5.  Dantrolene sodium: long-term effects in patients with muscle spasticity.

Authors:  R L Joynt
Journal:  Arch Phys Med Rehabil       Date:  1976-05       Impact factor: 3.966

6.  Increased risk for spondylitis stigmata in apparently healthy HL-AW27 men.

Authors:  L M Cohen; K K Mittal; F R Schmid; L F Rogers; K L Cohen
Journal:  Ann Intern Med       Date:  1976-01       Impact factor: 25.391

7.  Relationship between plasma concentration and effect of dantrolene sodium in man.

Authors:  W J Meyler; H W Mols-Thürkow; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

8.  Dantrolene-associated hepatic injury. Incidence and character.

Authors:  R Utili; J K Boitnott; H J Zimmerman
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

9.  Efficacy of dantrolene sodium in the treatment of spasticity.

Authors:  M Chipman; S Kaul; M Lambie
Journal:  Dis Nerv Syst       Date:  1974-09

10.  Action of dantrolene sodium in spasticity with low dependence on fusimotor drive.

Authors:  E Knutsson; A Martensson
Journal:  J Neurol Sci       Date:  1976-10       Impact factor: 3.181

View more
  12 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Pharmacokinetic evaluation of oral dantrolene in the dog.

Authors:  J L Haraschak; V C Langston; R Wang; C Riggs; C Fellman; M K Ross; C Bulla; K Lunsford; A Mackin; T Archer
Journal:  J Vet Pharmacol Ther       Date:  2013-11-13       Impact factor: 1.786

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

4.  Dantrolene reduces the threshold and gain for shivering.

Authors:  Chun-Ming Lin; Sharma Neeru; Anthony G Doufas; Edwin Liem; Yunus Muneer Shah; Anupama Wadhwa; Rainer Lenhardt; Andrew Bjorksten; Akiko Taguchi; Barhara Kabon; Daniel I Sessler; Andrea Kurz
Journal:  Anesth Analg       Date:  2004-05       Impact factor: 5.108

Review 5.  Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Authors:  Susanne Muehlschlegel; John R Sims
Journal:  Neurocrit Care       Date:  2008-08-12       Impact factor: 3.532

Review 6.  Recovery of neuronal and network excitability after spinal cord injury and implications for spasticity.

Authors:  Jessica M D'Amico; Elizabeth G Condliffe; Karen J B Martins; David J Bennett; Monica A Gorassini
Journal:  Front Integr Neurosci       Date:  2014-05-12

7.  Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse.

Authors:  Derek W Wang; Ekaterina I Mokhonova; Genevieve C Kendall; Diana Becerra; Yalda B Naeini; Rita M Cantor; Melissa J Spencer; Stanley F Nelson; M Carrie Miceli
Journal:  Mol Ther Nucleic Acids       Date:  2018-02-13       Impact factor: 8.886

8.  Intranasal administration of dantrolene increased brain concentration and duration.

Authors:  Jintao Wang; Yun Shi; Shuchun Yu; Yan Wang; Qingcheng Meng; Ge Liang; Maryellen F Eckenhoff; Huafeng Wei
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

9.  Intranasal Dantrolene as a Disease-Modifying Drug in Alzheimer 5XFAD Mice.

Authors:  Yun Shi; Lei Zhang; Xue Gao; Jing Zhang; Matan Ben Abou; Ge Liang; Qingcheng Meng; Adrian Hepner; Maryellen F Eckenhoff; Huafeng Wei
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 10.  Baclofen in the Therapeutic of Sequele of Traumatic Brain Injury: Spasticity.

Authors:  Adán Pérez-Arredondo; Eduardo Cázares-Ramírez; Paul Carrillo-Mora; Marina Martínez-Vargas; Noemí Cárdenas-Rodríguez; Elvia Coballase-Urrutia; Radamés Alemón-Medina; Aristides Sampieri; Luz Navarro; Liliana Carmona-Aparicio
Journal:  Clin Neuropharmacol       Date:  2016 Nov/Dec       Impact factor: 1.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.